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Active Cascade Screening in
Primary Inherited Arrhythmia Syndromes
Does It Lead to Prophylactic Treatment?
Nynke Hofman, MSC,* Hanno L. Tan, MD, PHD,† Marielle Alders, PHD,*
Irene M. van Langen, MD, PHD,* Arthur A. M. Wilde, MD, PHD†
Amsterdam, the Netherlands
Objectives The purpose of this study was to investigate the follow-up and treatment of the mutation-carrying relatives of a
proband with an inherited arrhythmia syndrome.
Background The congenital long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and
Brugada syndrome (BrS) are primary inherited arrhythmia syndromes that may cause syncope and sudden car-
diac death in young individuals. After establishing the disease-causing deoxyribonucleic acid (DNA) mutation in
probands, we actively conducted cascade screening to identify, most often asymptomatic, relatives who are also
at risk of life-threatening arrhythmias.
Methods We retrospectively collected data from our cardiogenetics database and patient records and analyzed whether
the identified carriers received prophylactic treatment.
Results From 1996 to 2008, 130 probands with a disease-causing mutation in one of the involved genes were identi-
fied, and 509 relatives tested positive for the disease-causing familial mutation. These subjects subsequently
underwent cardiologic investigation (electrocardiography, exercise testing, Holter monitoring, ajmaline testing,
echocardiography, where appropriate). After a mean follow-up of 69  31 months (LQTS), 60  19 months
(CPVT), and 56  21 months (BrS), treatment was initiated and ongoing in 65% (199 of 308), 71% (85 of 120),
and 6% (5 of 81) of the relatives in the LQTS, CPVT, and BrS families, respectively. Eight carriers were lost to
follow-up. Treatment included drug treatment (n  249) or implantation of pacemakers (n  26) or cardioverter-
defibrillators (n  14). All mutation carriers received lifestyle instructions and a list of drugs to be avoided.
Conclusions Cascade screening in families with LQTS, BrS, or CPVT, which was based on DNA mutation carrying and subse-
quent cardiologic investigation, resulted in immediate prophylactic treatment in a substantial proportion of carri-
ers, although these proportions varied significantly between the different diseases. (J Am Coll Cardiol 2010;55:
2570–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.063i
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aongenital long QT syndrome (LQTS), Brugada syndrome
BrS), and catecholaminergic polymorphic ventricular
achycardia (CPVT) are primary inherited arrhythmia syn-
romes that may cause syncope and sudden cardiac death in
oung individuals. These arrhythmias are almost exclusively
nherited as an autosomal dominant trait (1). In the past
ecade, the genetic basis of these arrhythmia syndromes has
een unraveled more and more. Predictive testing using
ascade screening in families with inherited arrhythmias is
ecoming more and more available as a result of this
rom the Departments of *Clinical Genetics and †Cardiology, Academic Medical
enter, Amsterdam, the Netherlands. Dr. Tan was supported by the Netherlands
rganization for Scientific Research (NWO, ZonMW-Vici 918.86.616). Dr. Wilde’s
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Manuscript received October 26, 2009; revised manuscript received December 1,
009, accepted December 7, 2009.ncreasing yield of molecular genetic analysis. Predictive
eoxyribonucleic acid (DNA) testing is warranted in these
amilies because first-degree relatives have a 50% risk of
arriership with a certain, although ill-defined, risk of lethal
vents and because most inherited arrhythmias can be
reated successfully. Therefore, we believe that it is very
mportant to inform affected families about the possibility of
reventive treatment and risk stratification after predictive
esting with the aim of preventing serious arrhythmias and
udden cardiac death. Due to the greatly varied expression
See page 2577
nd incomplete penetrance of these diseases, the decision to
tart treatment or not is not straightforward, particularly in
symptomatic patients. In our cardiogenetics department,
e have 10 years of experience with these cases and,
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June 8, 2010:2570–6 Prophylactic Treatment in Inherited Arrhythmiasherefore, a long follow-up period. We studied what per-
entage of patients (carriers) are actually treated, the
ollow-up of all patients (treated or not), and the reasons
hy treatment was started or not. When a causative
utation is identified in the proband, cascade screening of the
amily is feasible, allowing pre-symptomatic treatment and
ppropriate lifestyle adjustments (2). Predictive genetic testing
f relatives of a proband distinguishes carriers from noncarriers
f the disease-causing mutation. For carriers, treatment and/or
areful follow-up may be required. Noncarriers can be reas-
ured that they are not predisposed to life-threatening arrhyth-
ias and there is no risk of their offspring carrying the
utation.
LQTS and CPVT are heterogeneous. The major LQT
ypes are caused by mutations in KCNQ1 (LQT1), KCNH2
LQT2), and SCN5A (LQT3). Mutations in RYR2 are
esponsible for the dominant form of CPVT, whereas
ASQ2 mutations cause the recessive form. Whether pre-
ymptomatic treatment is necessary depends on the disease.
or both LQTS and CPVT, -adrenoceptor blockers are
he first choice of therapy (3). In LQTS patients, distinct
enotype-phenotype correlations have been reported (4–6).
ge at onset, symptom-related triggers, the ST-T segment
orphology of the electrocardiogram, and the response to
rugs are genotype specific. Timely treatment reduces the
isk of cardiac events significantly, by 62% to 95% and by
4% in LQT1 and LQT2, respectively (7,8). In particular,
n LQT1 -blocker efficacy is very high, with failures almost
xclusively due to noncompliance and/or the use of QT-
rolonging drugs (7). The choice of treatment in carriers of
QT3 is more debated (-blockers, prophylactic implant-
ble cardioverter-defibrillator [ICD], left cardiac sympa-
hetic denervation, or combinations thereof) (9,10). In BrS,
re-symptomatic testing is debated as well (11). In any case,
ll mutation carriers with LQTS or BrS should receive a list
ith drugs that must be avoided because they may precip-
tate lethal arrhythmias. Furthermore, all carriers should
eceive disease-related lifestyle modification instructions.
Taken together, treating physicians must contend with
ifficult therapeutic decisions, balancing the risks and ben-
fits of the various treatment modalities.
The aim of this retrospective study was to evaluate
hether pre-symptomatic genetic testing in the primary
rrhythmia syndromes resulted in prophylactic treatment in
utation carriers. In addition, we evaluated which factors
etermine whether to initiate treatment.
ethods
etting. In our multidisciplinary cardiogenetics outpatient
linic, genetic counseling and cascade screening for cardio-
enetic diseases starts with the affected patient, the proband.
ounseling sessions in probands and relatives combine the
onsultation of a cardiologist and a clinical geneticist or
enetic counselor. Support from a psychosocial worker is
outinely involved in predictive testing of minors. After the (etection of a pathogenic muta-
ion in the proband, the relatives
re informed by letters written by
he involved clinical geneticist or
enetic counselor and distributed
y the proband. When a relative
xpresses interest, he or she re-
eives an appointment for ge-
etic counseling. Once he or she
ecides to undergo direct predic-
ive genetic testing, he or she
ives written informed consent
or DNA testing and related re-
earch for follow-up. Before the counseling session for
redictive DNA testing, an electrocardiogram is obtained.
he electrocardiographic findings can be discussed during
he counseling session if the patient agrees, after discussing
he advantages and disadvantages of predictive testing. The
esults of predictive DNA testing take about 4 weeks after
ounseling. In the meantime, treatment can be recom-
ended if the results of the electrocardiogram (in LQTS)
re obviously abnormal, combined with typical symptoms
uch as syncope.
The results of the DNA testing are given personally at the
ardiogenetics outpatient clinic or by telephone, depending
n the preference of the relative. Carriers of the familial
utation are referred for subsequent cardiological evalua-
ion and regular follow-up, aiming to reduce sudden cardiac
eath. In addition to starting treatment with -blockers or
evices (pacemakers/ICDs), we counsel carriers, as a pre-
entive measure, about lifestyle changes and the avoidance
f particular drugs.
tudy population. From 1996 until the end of 2007, 349
onsecutive families were counseled because of LQTS,
PVT, or BrS. A pathogenic mutation was identified in
30 probands and active family screening (cascade screen-
ng) followed. Our study population consists of 509 consec-
tive relatives of 100 probands who tested positive for the
amilial mutation. Of the remaining 30 probands, the family
embers were not available, not tested, or tested negative.
linical data and follow-up. We retrospectively collected
linical data from our study cohort. These data included
ymptoms, the detailed family history of sudden cardiac
eath and syncope, and the use of drugs/devices. During the
rst visit, standard 12-lead electrocardiography in the su-
ine position was performed. After the relatives were
nformed of the results of genetic testing, the carriers were
eferred for an additional clinical workup, treatment if
ecessary, and follow-up. Information about treatment and
ollow-up was collected from patient records or by contact-
ng the treating physician. We determined the numbers of
atients in whom treatment (drugs, usually a -blocker,
acemaker, or ICD) was initiated, and compliance (defined
s the patient reporting that therapy was continued as
rescribed) with this treatment. We advise seeing all the
Abbreviations
and Acronyms
BrS  Brugada syndrome
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
DNA  deoxyribonucleic
acid
ICD  implantable
cardioverter-defibrillator
LQTS  long QT syndrometreated) patients at least once yearly and check the
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Prophylactic Treatment in Inherited Arrhythmias June 8, 2010:2570–6ollow-up and compliance with treatment of all patients by
he involved cardiologist. The start of follow-up (months) in
reated patients was defined as the start of treatment; this
as usually shortly after genetic testing. The start of
ollow-up in carriers without treatment was the moment
hen the results of pre-symptomatic testing were known.
he follow-up period was completed at the end of 2008 or
arlier in case the patient died.
lectrocardiographic measurements. In the LQTS rela-
ives, the R-R and QT intervals were manually measured in
ead V5, if possible, and the QT intervals were corrected
sing Bazett’s formula.
tatistical analysis. Quantitative variables are presented as
ean  SD and categorical variables as percentages. Com-
arisons were performed using chi-square tests. The pre-
ented p values are 2 sided and considered significant when
0.05. Calculations were performed with SPSS version 15
oftware (SPSS, Inc., Chicago, Illinois).
esults
ctive cascade screening yielded 509 relatives who tested
ositive for the familial disease-causing mutation in
CNQ1, KCNH2, SCN5A, RYR2, or CASQ2. The mean
ge of the relatives was younger in relatives of LQTS and
PVT families (34  22 years and 31  22 years,
espectively) than those of BrS families (48  20 years)
Table 1). This difference reflects our advice to test children
f LQTS and CPVT families at a younger age than those of
rS families because of an expected earlier onset, in general.
QTS. In LQTS, 199 of 308 mutation carriers were
reated (65%), and their mean follow-up period was 69
onths (range 6 to 150 months) (Table 2). The mean
ollow-up of the untreated mutation carriers was 54 months
range 18 to 121 months). The decision to initiate therapy
as mainly based on whether symptoms were present
Table 3), QTc duration, and family history. There was a
ociodemographic CharacteristicsTable 1 Sociodemographic Characteristics
LQTS BrS CPVT Total
Probands, n 66 24 10 100
Relatives, n 308 81 120* 509
Mean age, yrs (SD) 34 (22) 48 (20) 31 (22) 36 (22)
Male/female, n 150/158 36/45 50/70 236/273
One very large family was included with n  64 mutation carriers.
BrS  Brugada syndrome; CPVT  catecholaminergic polymorphic ventricular tachycardia;
TQS  long QT syndrome.
uration of Follow-UpTable 2 Duration of Follow-Up
Follow-Up (Months) LQTS, Treated LQTS, Untreated C
Patients, n 199 103
Mean SD 69 31 60 32
Range 6–150 18–121bbreviations as in Table 1.ignificant difference in QTc duration between treated and
ontreated carriers (p  0.0001) (Fig. 1). Still, in 59% (n 
08) of the LQT carriers with a QTc 460 ms, treatment
as initiated. All subjects, including those with normal
Tc, received a list of QT-prolonging drugs to avoid.
urthermore, we gave instructions about circumstances that
ay reduce serum potassium levels (diarrhea, vomiting) and
ay therefore increase the risk of arrhythmias.
In 163 subjects, -blockers alone were started, 26 muta-
ion carriers received a pacemaker, and 10 received an ICD
6 patients taking a -blocker and 4 patients not taking a
-blocker). All pacemakers were implanted in members of 2
arge (and probably related) families with LQT3, caused by
he 1795insD mutation in SCN5A. This aberrant gene
auses both an LQTS and a BrS phenotype, and pacemaker
herapy has proven to be effective (12). Ten patients
eceived an ICD because they had a severe phenotype. In 3
atients, this was caused by compound heterozygous muta-
ions; 2 mutation carriers were symptomatic despite
-blocker treatment and 5 had a first-degree relative with
udden cardiac death. The latter 5 all carried an SCN5A
utation, 4 of whom carried p.Ile1768Val (a mutation that
e consider particularly malignant). In LQTS type 1
utation carriers older than 20 years of age who are
symptomatic and have QTc values 500 ms, treatment is
ot routinely initiated, based on results of risk stratification
tudies in large LQT1 cohorts (4,8,13). In our series, 47 of
7 LQT1 mutation carriers are treated. Of the remaining 30
ubjects, 17 adult patients (older than 20 years of age) were
ot treated because they were asymptomatic and had a QTc
500 ms, whereas 2 declined treatment, and 10 were not
reated because their phenotype was completely normal.
mong these 10 subjects, 4 carried just 1 mutation and had
normal QTc duration, whereas the proband in this family
ad 2 mutations (compound heterozygous), and the other 6
ere not treated because both probands had a completely
ormal phenotype and QTc prolongation was discovered
oincidentally. One LQT1 carrier was lost to follow-up
Table 4).
Of 163 LQT2 patients, 121 were treated. Five patients
ied (see the following text). Forty-one carriers were not
reated because of the following reasons: treatment declined
n  3), not yet treated (n  5), asymptomatic and normal
Tc (n  20), carrier of only 1 mutation, whereas the
roband had 2 mutations (n  4), age older than 60 years
nd asymptomatic (n  9). One patient was lost to
ollow-up.
reated CPVT, Untreated BrS, Treated BrS, Untreated
32 5 76
19 44 17 56 21 40 24
14 18–66 30–78 18–102PVT, T
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June 8, 2010:2570–6 Prophylactic Treatment in Inherited ArrhythmiasOf 68 LQT3 carriers, 31 were treated, 1 died, 4 were lost
o follow-up, and 32 were untreated. Among them, 1
eclined pacemaker implantation and 31 patients were
ntreated, based on an asymptomatic status, age, and a
elatively normal electrocardiogram. Six subjects died during
ollow-up (Table 5). All but 1 were taking -blockers. An
utopsy was performed in none of them. One man died due
f cancer at the age of 74 years. Another man died after an
cute myocardial infarction complicated by ventricular fi-
rillation at the age of 59 years. Two others died within 2
ears after they were identified as carriers. A woman died
uddenly at the age of 52 years. She was treated with a
-blocker alone, although she had experienced cardiac arrest
years before, because she had significant cerebral impair-
ent. A 65-year-old woman (LQT3) died at rest shortly
fter pacemaker implantation while taking -blockers.
Figure 1 Number of Treated Patients Based on QTc
The corrected QT interval (QTc) of all long QT syndrome carriers was measured
on the baseline electrocardiogram before treatment was initiated. In this graph,
the baseline QTc durations of 193 of 194 treated carriers and 93 of 102
untreated carriers are included. QTc durations of the deceased patients and
those lost to follow-up (n  6 in both groups) are not included. There was a
significant difference in QTc duration between treated and nontreated carriers
(p  0.0001).
Initiation of Therapy in Subtypes of LQTS*Table 3 Initiation of Therapy in Subtypes of
Treatment Symptomatic/Asymptomatic
-blocker, n Symptomatic
Asymptomatic
Pacemaker, n Symptomatic
Asymptomatic
ICD, n Symptomatic
Asymptomatic
Totally treated, n
*Deceased patients included. †SCN5A: 1795insD mutation carriers.
ICD  implantable cardioverter-defibrillator; other abbreviation as i*ompliance with therapy was verified after the patients’
eath by interviewing close relatives.
PVT. Of 10 families, 120 relatives tested positive (64
rom 1 family). The mean follow-up of treated CPVT
arriers was 60 months (range 18 to 114 months).
ighty-five of them were treated with a -blocker (71%),
received an ICD as well, and 1 carrier underwent a left
ardiac sympathetic denervation (just like her sister, the
roband) (14).
In general, treatment with a -blocker was recommended
or all carriers until an advanced age (about 70 years old).
leven carriers were not treated because they carried a
eterozygous CASQ2 mutation, whereas the proband was
omozygous. One other patient was considered too young
o start treatment.
Four mutation carriers from a single family exhibited no
entricular ectopic beats during exercise testing. Whether
he involved RYR2 mutation in this particular family
c.14757-6CT; c.14757-7TA in intron 103) is disease
ausing is still being debated. Not all CPVT carriers
ollowed the advice to take -blockers; thus, 17 were
ntreated, including 5 persons aged older than 70 years. The
ean follow-up of untreated CPVT carriers was 44 months
range 18 to 66 months). Two patients were lost to
ollow-up; no one died during follow-up.
rS. Among 81 BrS carriers, 5 were treated (6.2%). Four of
hem received an ICD, but had no ICD shocks during
ollow-up. One mutation carrier had already received a
acemaker before he tested positive for the familial muta-
ion because of conduction abnormalities. The mean
ollow-up duration was 56 months (range 30 to 78 months)
n treated carriers, and 40 months (range 18 to 102 months)
n untreated carriers. No one died during follow-up.
*
QTS1 LQTS2 LQTS3
10 23 0
36 93 1
0 1 5†
0 1 19† (1  -blocker)
-blocker) 3 ( -blocker) 1
0 0 5
47 121 31
1.
umber of Subjects With Follow-UpTable 4 Number of Subjects With Follow-Up
Treatment
Initiated*
No
Treatment Lost to Follow-Up Death
LQTS, n (%) 199 (65) 103 (33) 6 6 (2)
CPVT, n (%) 85 (71) 33 (28) 2 0
BrS, n (%) 5 (6) 76 (94) 0 0LQTS
L
1 (Deceased carriers included.
Abbreviations as in Table 1.
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Prophylactic Treatment in Inherited Arrhythmias June 8, 2010:2570–6iscussion
n our consecutive series, we found that immediate prophy-
actic treatment was started in a substantial proportion of
arriers of a mutation causal to one of main arrhythmia
yndromes (289 of 509, 57%). Initiation of therapy strongly
epends of the type of disease. In LQTS and CPVT, 65%
nd 71%, respectively, of the mutation carriers were treated
fter a mean follow-up of almost 6 years; in BrS, only 6%
ere treated. Because the risks of and treatment options for
rrhythmias in the different diseases are not completely
omparable, the results are discussed separately.
QTS. Among our 308 LQTS patients (LQT1, n  77;
QT2, n 63, and LQT3, n 68), 65% were treated after
mean follow-up of 69 months. Seven patients (2%)
eclined therapy, or discontinued taking a -blocker daily.
ompliance with therapy and follow-up in this patient
roup, therefore, is close to 100%.
Once treatment is started and evaluated, patients attend
he outpatient clinic of the cardiologist once or twice yearly.
n LQT1 patients, symptoms usually develop during phys-
cal activity (4,15), especially swimming (4,16). Because the
QT1 phenotype manifests at a young age, children are
ften treated well before they are 5 years old. The risk of
vents is strongly dependent on QTc duration (4,5,17).
ther recently investigated predictors of events are the
ocation of the mutation in the LQT1-associated gene
KCNQ1) and the biophysical effects of the mutation:
atients with transmembrane mutations have longer QTc
urations than patients with mutations in the C-terminus
ocation, whereas dominant-negative mutations are associ-
ted with more events compared with those that cause
aploinsufficiency (8). It is important to note that some
pecific mutations seem to have a significant malignant
utcome (18).
In LQT2, there is more evidence of a first event at a later
ge than LQT1 (i.e., from puberty onward) (4,5). In
ddition to treatment with a -blocker and the avoidance of
T-prolonging drugs, we advise LQT2 carriers actively
hange some lifestyle elements, such as the avoidance of
udden loud noises (e.g., ringtones and alarm clocks),
eceased LQTS Patients During Follow-UpTable 5 Deceased LQTS Patients During Follow-Up
Patient # Sex
Type
of LQTS
Age at
Testing, yrs
History
of Syncope
1 Male 2 64  Pro
2 Male 2 57 
3 Male 2 41  Bis
4 Female 2 44  Me
5 Female 2 44  Me
6 Female 3 65  Me
18 months after initiation of therapy (-blocker). †Low dose because of asthmatic disease. ‡4
-blocker.
SCD  sudden cardiac death; other abbreviations as in Tables 1 and 3.ecause sudden auditory sensations often trigger arrhyth- pias in LQT2 (16). Female LQT2 carriers who desire to
ecome pregnant receive extra monitoring after delivery
ecause they have an increased risk of extra QTc prolonga-
ion shortly after delivery, possibly because of the combined
ffects of hormonal imbalance, stress, and fatigue (19–21).
LQT3 carriers show a large variation in phenotype.
owever, almost 50% of studied subjects (n  30) in our
eries carry the 1795insD mutation in SCN5A. They exhibit
high incidence of nocturnal sudden death, bradycardia-
ependent QT prolongation, intrinsic sinus node dysfunc-
ion, and generalized conduction abnormalities. Pacemaker
mplantation, in this large family with the 1795insD muta-
ion, was shown to be effective in preventing sudden
eath (12).
In general, the management of LQT3 patients is com-
lex. Although treatment with -blockers lowers the heart
ate, it has been observed that QTc duration in LQT3
atients increases even more at low heart rates (e.g., during
he night), suggesting a higher risk of life-threatening
rrhythmias. However, there is no clear evidence that
-blockers are contraindicated in LQT3 patients, and,
nless patients had become symptomatic in the first year of
ife, they seem to be beneficial (10). Thorough examination
Holter monitoring) is recommended before starting
-blocker therapy and should be repeated during therapy.
Six LQTS patients died during follow-up (Table 5). Four
f them died suddenly and unexpectedly without explana-
ion. There was no autopsy performed of these patients, so
e cannot exclude that cardiovascular heart diseases or other
auses contributed to their death. Still, it is of concern that
LQT2 patients died shortly after treatment was started (8
onths, and 4 months before death, respectively) and 1
QT3 patient died within 10 days despite -blocker and
AI pacemaker therapy. Although difficult to accept, and
ealizing these numbers are too small for conclusions, one
as to consider the possibility that -blocker therapy con-
ributed to their death. Repeated monitoring (electrocardio-
raphic, Holter) shortly after initiation of treatment thus
eems mandatory.
Our results show an important clinical implication of
Treatment
Age at
Death, yrs
Cause
of Death
ol, 3  80 mg, aldactone, and potassium;
age 71 yrs
74 Cancer
— 59 Acute myocardial
infarction
l, 1  10 mg 43 SCD*
ol, 1  25 mg† 44 SCD‡
ol, 1  100 mg 52 SCD
ol, 1  150 and AAI pacemaker 65 SCD§
s after initiation of therapy (-blocker). §10 days after pacemaker implantation, combined withpanol
ICD at
oprolo
toprol
toprol
toprol
monthositive genetic testing in families with LQTS: of all
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June 8, 2010:2570–6 Prophylactic Treatment in Inherited Arrhythmiasatients with a QTc 460 ms, 59% (n  108) were treated
fter cardiologic investigation. These patients probably
ould have been missed if just electrocardiography was
erformed without genetic testing. In addition to that, as
entioned before, all LQT carriers receive lifestyle instruc-
ions and a list of QT-prolonging drugs to be avoided (7).
PVT. Seventy-three percent of the carriers of the familial
PVT mutation are treated (successfully). CPVT is char-
cterized by exercise-induced or acute adrenergic stress–
nduced polymorphic ventricular arrhythmias, often causing
yncope; a normal baseline electrocardiogram; the absence
f structural cardiac abnormalities; and a high mortality rate
22–24). Genetic testing is important because the disease
enetrance is not 100%, which suggests that a normal
xercise test does not exclude carriership automatically.
ymptoms usually develop during childhood or adolescence.
n a substantial portion of cases, cardiac arrest is the first
anifestation of the disease (23). Because the onset of the
isease already manifests at a young age, we advise our
amilies to test their children at an early age. As a principle,
ll carriers are treated with a -blocker. Although
-blockers do not seem to abolish exercise-induced ventric-
lar ectopy completely, they do protect against serious
rrhythmias in most patients. In 1 patient (a sister of the
roband), significant arrhythmias continued despite
-blocker therapy; she successfully underwent left cardiac
ympathetic denervation (13). One patient received an ICD
ecause of psychosocial distress caused by mutation
arriership.
New treatments for CPVT are being considered. Because
reliminary evidence suggests that flecainide might be
uccessful (25), we are starting a study in a larger group of
atients. In general, we advise all carriers to avoid intensive
ports and exercise.
rS. Of our 81 BrS mutation carriers, 5 were treated with
n ICD or pacemaker. Four patients received an ICD
ecause they had syncope (n  2) or expressed an explicit
reference for an ICD after extensive counseling (n  2).
ll 4 had a first-degree relative who had had a sudden
nexplained death. All patients who are tested positive for
rS receive a list of drugs to avoid (26). Moreover, they are
dvised to use antipyretic drugs during fever because a
ubstantial proportion of BrS patients exhibit more severe
lectrocardiographic abnormalities and an increased risk of
ymptoms during fever (27). Accordingly, we advise all
atients to visit the hospital during at least 1 fever episode
o establish whether their electrocardiographic abnormali-
ies worsen with fever. The age at which symptoms first
ccur is consistently during approximately the fourth decade
f life in all studies, with no definite explanation for this
bservation. All carriers see a cardiologist once yearly for
valuation. Although symptomatic children were described
arely, recently more and more evidence is appearing about
bnormal electrocardiograms in children with or without
ymptoms (28). In general, asymptomatic carriers with a
ormal baseline electrocardiogram seem to have a low riskf arrhythmias, although this is debated. In addition to
reatment with an ICD, quinidine therapy is used in some
atients. A registry assessing the effectiveness of quinidine
as recently been suggested (29).
Taken together, the results of this study show quite a
igh number of disease carriers of LQTS and CPVT in
hich treatment is initiated shortly after confirmation of
utation carriership. Although it is impossible to quantify
he benefit of this approach, it is safe to state that life-
hreatening arrhythmias are probably averted. In BrS, this
ssumption is less obvious because none of the BrS patients
ad serious arrhythmias during follow-up and none of the 4
ith ICDs has had an appropriate shock.
Indeed, the follow-up of BrS carriers is possibly the most
ifficult part of the study population because the treatment
ptions are limited and extreme (“wait and see” policy versus
mplanting an ICD). The large differences between the
henotypes of the Brugada probands and relatives are still
nexplained, mainly due to the still-limited knowledge of
he genetic causes of BrS.
onclusions
ctive cascade screening for disease carriership of relatives
f LQTS, CPVT, or BrS probands leads to immediate
rophylactic treatment in a substantial proportion of disease
arriers. In LQTS and CPVT, 65% and 71%, respectively,
f the carriers are treated. In BrS, only 6% of the mutation
arriers are treated. These differences reflect differences in
reatment options and variations in disease expression and
enetrance. A large number of carriers are treated pre-
ymptomatically; these patients would have been missed
ithout genetic testing. These and other data point to the
eed to identify all affected family members, independently
f their QTc or symptoms, to prevent deaths. All LQTS
nd BrS carriers should receive a list of drugs to be avoided.
ll LQT1, LQT2, BrS, and CPVT carriers should receive
ifestyle modification instructions.
eprint request and correspondence: Dr. Arthur A. M. Wilde,
cademic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam,
he Netherlands. E-mail: a.a.wilde@amc.nl.
EFERENCES
1. Wilde AA, Bezzina CR. Genetics of cardiac arrhythmias. Heart
2005;91:1352–8.
2. van Langen IM, Hofman N, Tan HL, Wilde AA. Family and
population strategies for screening and counseling of inherited cardiac
arrhythmias. Ann Med 2004;36 Suppl 1:116–24.
3. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of
-blocker therapy in congenital long-QT syndrome. Circulation
2000;101:616–23.
4. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype
correlation in the long QT syndrome; gene-specific triggers for
life-threatening arrhythmias. Circulation 2001;119:215–21.5. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the
long-QT syndrome. N Engl J Med 2003;348:1866–74.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
K
2576 Hofman et al. JACC Vol. 55, No. 23, 2010
Prophylactic Treatment in Inherited Arrhythmias June 8, 2010:2570–66. Tan HL, Bardai A, Shimizu W, et al. Genotype-specific onset of
arrhythmias in congenital long-QT syndrome: possible therapy impli-
cations. Circulation 2006;114:2096–103.
7. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-
blockers in long-QT syndrome type 1: contribution of noncompliance
and QT-prolonging drugs to the occurrence of beta-blocker treatment
“failures.” Circulation 2009;119:215–21.
8. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1
long-QT syndrome by location, coding type, and biophysical function
of mutations involving the KCNQ1 gene. Circulation 2007;115:
2481–9.
9. Schwartz PJ. Cutting nerves and saving lives. Heart Rhythm 2009;6:
760–3.
0. Schwartz PJ, Spazzolini DVM, Crotti L. All LQT3 patients need an
ICD: true or false? Heart Rhythm 2009;6:113–20.
1. Oliva A, Bjerregaard P, Hong K, et al. Clinical heterogeneity in
sodium channelopathies. What is the meaning of carrying a genetic
mutation. Cardiology 2008;110:116–22.
2. van den Berg MP, Wilde AA, Viersma TJW, et al. Possible brady-
cardic mode of death and successful pacemaker treatment in a large
family with features of long QT syndrome type 3 and Brugada
syndrome. J Cardiovasc Electrophysiol 2001;12:630–6.
3. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of the genotype on
the clinical course of the long-QT syndrome. N Engl J Med 1998;
339:960–5.
4. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic
denervation for catecholaminergic polymorphic ventricular tachycar-
dia. N Engl J Med 2008;358:2024–9.
5. Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as
a trigger for arrhythmic events differentiate HERG-related (LQTS2)
patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol
1999;33:327–32.
6. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman
MJ. Spectrum and frequency of cardiac channel defects in swimming-
triggered arrhythmia syndromes. Circulation 2004;110:2119–24.
7. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT
syndrome loci and cardiac events among patients treated with beta-
blockers. JAMA 2004;292:1341–4. p8. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT
syndrome mutation KCNQ1/A341V causes unusually severe clinical
manifestations in patients with different ethnic backgrounds: toward a
mutation-specific risk stratification. Circulation 2007;116:2366–75.
9. Seth R. Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy.
J Am Coll Cardiol 2007;49:1092–8.
0. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the
risk for cardiac events in patients with hereditary long QT syndrome.
Circulation 1998;97:451–6.
1. Meregalli PG, Westendorp IC, Tan HL, Elsman P, Kok WE, Wilde
AA. Pregnancy and the risk of torsades de pointes in congenital
long-QT-syndrome. Neth Heart J 2008;16:422–5.
2. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P.
Catecholaminergic polymorphic ventricular tachycardia in children. A
7-year follow-up of 21 patients. Circulation 1995;91:1512–9.
3. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular
characterization of patients with catecholaminergic polymorphic ven-
tricular tachycardia. Circulation 2002;106:69–74.
4. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors
of arrhythmic events in catecholaminergic polymorphic ventricular
tachycardia. Circulation 2009;119:2426–34.
5. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents cat-
echolaminergic polymorphic ventricular tachycardia in mice and hu-
mans. Nat Med 2009;15:380–3.
6. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada
syndrome patients: review of the literature, recommendations and an
up-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:
1335–41.
7. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever
increases the risk for cardiac arrest in the Brugada syndrome. Ann
Intern Med 2008;149:216–8.
8. Probst V, Denjoy I, Meregalli PG, et al. Clinical aspects and prognosis
of Brugada syndrome in children. Circulation 2007;115:2042–8.
9. Viskin S, Wilde AA, Tan HL, Antzelevitch C, Shimizu W, Belhassen
B. Empiric quinidine therapy for asymptomatic Brugada syndrome:
time for a prospective registry. Heart Rhythm 2009;6:401–4.
ey Words: cardiogenetics y follow-up y inherited arrhythmias y
rophylactic treatment.
